发明名称 ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40
摘要 Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
申请公布号 US2017015754(A1) 申请公布日期 2017.01.19
申请号 US201615259828 申请日期 2016.09.08
申请人 Bristol-Myers Squibb Company ;Domantis Limited 发明人 SURI Anish;SHERIFF Steven;SUCHARD Suzanne;YAMNIUK Aaron;KRYSTEK Stanley;TAMURA James;BRYSON James;GRANT Steven;DREW Philip
分类号 C07K16/28;A61K39/395;A61K45/06;C07K16/18 主分类号 C07K16/28
代理机构 代理人
主权项 1. An antibody polypeptide comprising a first variable domain, wherein said antibody polypeptide specifically binds an epitope of human CD40, wherein the antibody polypeptide competes with the binding of domain antibody (dAb) BMS3h-56-269 (SEQ ID NO: 417) to CD40, wherein CD40 comprises the amino acid sequence of SEQ ID NO: 1, and wherein the epitope comprises at least one CD40 amino acid residue selected from the group consisting of Trp109, Leu121, His122, Ser124, Ser156, Ala157, Phe158, Glu159, and His162.
地址 Princeton NJ US